EYP-1901 for Wet Age-Related Macular Degeneration

EYP-1901 for Wet Age-Related Macular Degeneration
56%45%34%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 45.0%
EyePoint Pharmaceuticals, Inc. ($EYPT)
No stock close$13.79$12.60$11.41May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • EYPT $11.70May 19 • EYPT $11.82May 20 • EYPT $12.50May 21 • EYPT $12.78May 22 • EYPT $12.93May 26 • EYPT $13.35May 27 • EYPT $13.16May 28 • EYPT $13.50

Will this trial show a positive result on Average change in best corrected visual acuity (BCVA), Weeks 52 and 56?

Paper Trading
Create account to trade
Scientific editorial illustration for Wet Age-Related Macular Degeneration

Wet Age-Related Macular Degeneration

Wet age-related macular degeneration damages central vision by leaking abnormal blood vessels behind the retina. Best corrected visual acuity means letters read with best glasses, so changes show whether treatment preserves everyday sight.